Results 11 to 20 of about 8,147 (216)
Treatment planning software for HIPEC [PDF]
, 2023 Peritoneal metastases (PM) predominantly originate from primary cancers such as colorectal, ovarian and gastric cancer. Survival rates decrease dramatically when metastases develop in the peritoneal cavity. The combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) offers a treatment option that can ...
Löke, D.R.
core +14 more sources
HIPEC for ovarian cancer [PDF]
, 2021 Eierstokkanker staat in de top 10 van kankerdiagnoses bij vrouwen wereldwijd. Ongeveer 70-80% van de patiënten met eierstokkanker, heeft deze ziekte in stadium III of IV, waarbij de ziekte is uitgezaaid naar het buikvlies of buiten de buikholte. De behandeling van eierstokkanker bestaat uit chirurgie, chemotherapie en doelgerichte onderhoudstherapie ...
Koole, S.N.
core +6 more sources
The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: HIPEC Technologies [PDF]
Annals of Surgical OncologyThis manuscript reports the results of an international consensus on technologies of hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) performed with the following goals: To provide recommendations for the technological parameters to perform HIPEC.
Kurt, Van der Speeten +6 more
openaire +3 more sources
Serum procalcitonin improves diagnosis of infectious complications after CRS/HIPEC [PDF]
World Journal of Surgical Oncology, 2023 Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) improve the survival of selected patients with peritoneal metastasis. A major cause of treatment-related morbidity after CRS/HIPEC is infection and sepsis. HIPEC
Lilian Roth +6 more
doaj +2 more sources
Hypertherme intraperitoneale chemotherapie (HIPEC) [PDF]
Huisarts en wetenschap, 2013 Hemmer PHJ, Van Leeuwen BL. Hyperthermic intraperitoneal chemotherapy (HIPEC). Huisarts Wet 2013;56(1):36-9.Surgery forms the basis of cancer therapy, and surgical resection sometimes improves survival in metastatic disease. One such surgical approach is cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Hemmer, Patrick, Van Leeuwen, Barbara
openaire +4 more sources
Is there a role for HIPEC in ovarian cancer? [PDF]
Archives of Gynecology and Obstetrics, 2018 Hyperthermic intraperitoneal chemotherapy (HIPEC) is promoted by some as a standard treatment for peritoneal carcinomatosis of epithelial ovarian cancer (EOC) and other tumor entities, despite lack of robust data supporting this. Publicly available evidence addressing the value of HIPEC in EOC is rather inconclusive, revealing contradictory and ...
Philipp Harter +7 more
openaire +2 more sources
Development of a Nanocrystalline Paclitaxel Formulation for Hipec Treatment [PDF]
Pharmaceutical Research, 2012 To develop a nanocrystalline paclitaxel formulation with a high paclitaxel-to-stabilizer ratio which can be used for hyperthermic intraperitoneal chemotherapy (HIPEC).Paclitaxel (PTX) nanocrystals were prepared via wet milling using Pluronic F127(®) as stabilizer.
De Smet, Lieselotte +6 more
openaire +5 more sources
HIPEC and recurrent EOC.xls [PDF]
, 2022 HIPEC and recurrent ...
Dong Yang (14177049)
core +1 more source
Current Research and Development in Hyperthermic Intraperitoneal Chemotherapy (HIPEC)—A Cross-Sectional Analysis of Clinical Trials Registered on ClinicalTrials.gov [PDF]
, 2023 Introduction: Over the past two decades, cytoreductive surgery and HIPEC has improved outcomes for selected patients with peritoneal metastasis from various origins.
Lehmann, Kuno +13 more
core +1 more source
HIPEC and immunotherapy for ovarian cancer [PDF]
Ovarian cancer poses a significant global health burden, with mortality rates exceeding those of other gynecologic cancers. Despite initial sensitivity to chemotherapy and treatment with cytoreductive surgery, most patients experience recurrent disease and require multiple lines of therapy. Over time, relapses become increasingly resistant to treatment,
Aronson, S.L.
core +5 more sources